Chilukuri Suneel, Robb Christopher W, Weiner Steven F, Grossman Jody
J Drugs Dermatol. 2018 Jul 1;17(7):745-748.
Primary axillary hyperhidrosis (PAH), or excessive sweating limited to the axillary area, is a debilitating disease that severely and negatively impacts social and psychological well-being. Several treatment options are available for PAH; however, these options have been shown to provide varying effectiveness. Recent studies have suggested another treatment alternative offering an effective PAH treatment option with reported long-term results. High intensity focused fractional radiofrequency (HIFRF) microneedling is FDA cleared for the treatment of facial wrinkles. The system is designed with a unique technology that is safe for use on patients presenting with all skin types. Based on its unique design and the clinical trial experience reported in the literature by Kim, et al1 and others,2,5 we offer it to our patients as a beneficial treatment option for primary axillary hyperhidrosis (PAH). We present here a clinical experience summary from three US centers providing hyperhidrosis treatments using the high-intensity radio-frequency device, including treatment parameters, clinical outcomes, and pre- and post-treatment images. J Drugs Dermatol. 2018;17(7):745-748.
原发性腋窝多汗症（PAH），即仅限于腋窝区域的过度出汗，是一种使人衰弱的疾病，会对社交和心理健康产生严重的负面影响。PAH有多种治疗选择；然而，这些选择的有效性各不相同。最近的研究提出了另一种治疗方法，它提供了一种有效的PAH治疗方案，并报告了长期效果。高强度聚焦微针射频（HIFRF）已获美国食品药品监督管理局（FDA）批准用于治疗面部皱纹。该系统采用独特技术设计，对所有皮肤类型的患者使用都是安全的。基于其独特的设计以及Kim等人1及其他研究2,5在文献中报道的临床试验经验，我们将其作为原发性腋窝多汗症（PAH）的一种有益治疗选择提供给我们的患者。我们在此展示来自美国三个提供多汗症治疗的中心的临床经验总结，包括治疗参数、临床结果以及治疗前后的图像。《药物皮肤病学杂志》。2018年；17(7):745 - 748。
